TALPHERA, INC. 8K

Talphera, Inc. announced its Q2 2026 financial results, progress of its NEPHRO CRRT nafamostat study toward year-end completion, favorable draft KDIGO guideline recognition, increased CRRT market estimates, regained Nasdaq bid-price compliance, and current liquidity, and scheduled a same-day investor call.

On August 12, 2026, Talphera, Inc. reported its second quarter 2026 financial results and provided a corporate update highlighting that its NEPHRO CRRT Phase 3 study of nafamostat (Niyad) has reached 75% enrollment and remains on track for completion by year-end, that all target clinical sites are now activated, and that the draft 2026 KDIGO acute kidney injury guidelines now recognize nafamostat as an acceptable CRRT anticoagulant, improving its potential commercial positioning. The company also disclosed updated market research estimating approximately 200,000 annual U.S. CRRT procedures in 2027, a 21% increase over prior estimates, noted it has regained compliance with Nasdaq’s $1.00 bid price requirement, and reported a cash and investments balance of $17.1 million as of June 30, 2026, second quarter combined R&D and SG&A expenses of $3.9 million, and a net loss attributable to common shareholders of $4.3 million, or $0.06 per share. Talphera announced a same-day investor conference call and webcast to discuss these results and the business outlook for nafamostat-based programs.

Filing Facts

CIK

1427925

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-027311

Alert Tier

6